The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation in an ovariectomized rat model

Clinical Epigenetics

Volumn 8, Issue 1, 2016, Pages

  Gjoksi, Bebeka ^a,c   Ghayor, Chafik ^a   Bhattacharya, Indranil ^a,b   Zenobi Wong, Marcy ^a,c   Weber, Franz E ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

Adipocytes; Epigenetic modulator; Osteoporosis; Small inhibitor molecule

Indexed keywords

1 METHYL 2 PYRROLIDINONE; LEPTIN; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BRD2; PROTEIN BRD4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; BRD2 PROTEIN, MOUSE; BRD4 PROTEIN, MOUSE; N-METHYLPYRROLIDONE; NONHISTONE PROTEIN; NUCLEAR PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; ESTROGEN DEFICIENCY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MESENCHYMAL STEM CELL; NONHUMAN; OVARIECTOMY-INDUCED OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION; WEIGHT GAIN; WHITE ADIPOSE TISSUE; 3T3-L1 CELL LINE; ADVERSE EFFECTS; ANIMAL; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; OSTEOPOROSIS; OVARIECTOMY;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; CELL DIFFERENTIATION; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; NUCLEAR PROTEINS; OSTEOPOROSIS; OVARIECTOMY; PROTEIN BINDING; PYRROLIDINONES; RATS; TRANSCRIPTION FACTORS; WEIGHT GAIN;

EID: 84964241059     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-016-0209-2     Document Type: Article

References (43)

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276–87. doi:10.1016/S0140-6736(10)62349-5.
2. van Seumeren I. Weight gain and hormone replacement therapy: are women’s fears justified? Maturitas. 2000;34 Suppl 1:S3–8.
3. Clegg DJ. Minireview: the year in review of estrogen regulation of metabolism. Mol Endocrinol. 2012;26(12):1957–60. doi:10.1210/me.2012-1284.
4. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheum. 2006;2(1):35–43.
5. James AW. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation. Scientifica (Cairo). 2013;2013:684736. doi:10.1155/2013/684736.
6. Chen Q, Shou P, Zheng C, Jiang M, Cao G, Yang Q et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts[quest]. Cell Death Differ. 2016. doi:10.1038/cdd.2015.168
7. Li GW, Xu Z, Chen QW, Chang SX, Tian YN, Fan JZ. The temporal characterization of marrow lipids and adipocytes in a rabbit model of glucocorticoid-induced osteoporosis. Skeletal Radiol. 2013;42(9):1235–44. doi:10.1007/s00256-013-1659-7.
8. Patsch JM, Li X, Baum T, Yap SP, Karampinos DC, Schwartz AV, et al. Bone marrow fat composition as a novel imaging biomarker in postmenopausal women with prevalent fragility fractures. J Bone Miner Res. 2013;28(8):1721–8. doi:10.1002/jbmr.1950.
9. Kanaley JA, Sames C, Swisher L, Swick AG, Ploutz-Snyder LL, Steppan CM, et al. Abdominal fat distribution in pre- and postmenopausal women: the impact of physical activity, age, and menopausal status. Metabolism. 2001;50(8):976–82. doi:10.1053/meta.2001.24931.
10. Douchi T, Yamamoto S, Yoshimitsu N, Andoh T, Matsuo T, Nagata Y. Relative contribution of aging and menopause to changes in lean and fat mass in segmental regions. Maturitas. 2002;42(4):301–6.
11. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab. 2011;22(1):24–33. doi:10.1016/j.tem.2010.10.002.
12. Poledne R, Lorenzova A, Stavek P, Valenta Z, Hubacek J, Suchanek P, et al. Proinflammatory status, genetics and atherosclerosis. Physiol Res. 2009;58 Suppl 2:S111–8.
13. Lizcano F, Guzman G. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Int. 2014;2014:757461. doi:10.1155/2014/757461.
14. Krum SA, Brown M. Unraveling estrogen action in osteoporosis. Cell Cycle. 2008;7(10):1348–52.
15. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002;16(1):22–6. doi:10.1101/gad.948702.
16. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33(Suppl):245–54. doi:10.1038/ng1089.
17. Marchand JR, Caflisch A. Binding mode of acetylated histones to bromodomains: variations on a common motif. ChemMedChem. 2015;10(8):1327–33. doi:10.1002/cmdc.201500141.
18. Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12(7):465–77. doi:10.1038/nrc3256.
19. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol. 2013;190(7):3670–8. doi:10.4049/jimmunol.1202838.
20. Huang H, Zhang J, Shen W, Wang X, Wu J, Wu J, et al. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails. BMC Struct Biol. 2007;7:57. doi:10.1186/1472-6807-7-57.
21. Hu YJ, Belaghzal H, Hsiao WY, Qi J, Bradner JE, Guertin DA, et al. Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. Nucleic Acids Res. 2015;43(16):7790–804. doi:10.1093/nar/gkv645.
22. Ghayor C, Correro RM, Lange K, Karfeld-Sulzer LS, Gratz KW, Weber FE. Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone. J Biol Chem. 2011;286(27):24458–66. doi:10.1074/jbc.M111.223297.
23. Miguel BS, Ghayor C, Ehrbar M, Jung RE, Zwahlen RA, Hortschansky P, et al. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Tissue Eng Part A. 2009;15(10):2955–63. doi:10.1089/ten.TEA.2009.0009.
24. Gjoksi B, Ghayor C, Siegenthaler B, Ruangsawasdi N, Zenobi-Wong M, Weber FE. The epigenetically active small chemical N-methyl pyrrolidone (NMP) prevents estrogen depletion induced osteoporosis. Bone. 2015;78:114–21. doi:10.1016/j.bone.2015.05.004.
25. Ghayor C, Gjoksi B, Siegenthaler B, Weber FE. N-methyl pyrrolidone (NMP) inhibits lipopolysaccharide-induced inflammation by suppressing NF-kappaB signaling. Inflamm Res. 2015;64(7):527–36. doi:10.1007/s00011-015-0833-x.
26. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641–50. doi:10.1002/jor.1100090504.
27. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.
28. Astudillo P, Rios S, Pastenes L, Pino AM, Rodriguez JP. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem. 2008;103(4):1054–65. doi:10.1002/jcb.21516.
29. Florence B, Faller DV. You bet-cha: a novel family of transcriptional regulators. Front Biosci. 2001;6:D1008–18.
30. Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP, et al. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women’s Health Study. Arch Intern Med. 2000;160(14):2117–28.
31. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Menopause-related changes in body fat distribution. Ann N Y Acad Sci. 2000;904:502–6.
32. de Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE. Diet-induced obesity leads to the development of leptin resistance in vagal afferent neurons. Am J Physiol Endocrinol Metab. 2011;301(1):E187–95. doi:10.1152/ajpendo.00056.2011.
33. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51(6):1884–8.
34. Takahashi M, Funahashi T, Shimomura I, Miyaoka K, Matsuzawa Y. Plasma leptin levels and body fat distribution. Horm Metab Res. 1996;28(12):751–2. doi:10.1055/s-2007-979893.
35. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME. Playing with bone and fat. J Cell Biochem. 2006;98(2):251–66. doi:10.1002/jcb.20777.
36. Zhang JF, Fu WM, He ML, Wang H, Wang WM, Yu SC, et al. MiR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Osterix. Mol Biol Cell. 2011;22(21):3955–61. doi:10.1091/mbc.E11-04-0356.
37. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res. 2007;22(10):1603–11. doi:10.1359/jbmr.070701.
38. Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK, Denis GV. Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem J. 2010;425(1):71–83. doi:10.1042/BJ20090928.
39. Zang K, Wang J, Dong M, Sun R, Wang Y, Huang Y, et al. Brd2 inhibits adipogenesis via the ERK1/2 signaling pathway in 3T3-L1 adipocytes. PLoS One. 2013;8(10), e78536. doi:10.1371/journal.pone.0078536.
40. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, et al. Small-molecule inhibition of BRDT for male contraception. Cell. 2012;150(4):673–84. doi:10.1016/j.cell.2012.06.045.
41. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–73. doi:10.1038/nature09504.
42. Qian S-W, Li X, Zhang Y-Y, Huang H-Y, Liu Y, Sun X, et al. Characterization of adipocyte differentiation from human mesenchymal stem cells in bone marrow. BMC Dev Biol. 2010;10(1):1–11. doi:10.1186/1471-213x-10-47.
43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.